Global Registry for Long-Term Follow-up of Posoleucel

• Research type

  Research Study

• Full title

  Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105)

• IRAS ID

  1005578

• Contact name

  Dawid Olejniczak

• Contact email

  ALVRRegistryP-105-401_4690-0012@iconplc.com

• Sponsor organisation

  AlloVir, Inc.

• Eudract number

  2022-000763-45

• ISRCTN Number

  ISRCTN31439492

• Research summary

  Posoleucel (or ALVR105) is a research medicine that contains T-cells made from healthy human donors to defend patients against specific viruses. The purpose of this registry study is to follow up with children and adult patients who were enrolled in Posoleucel clinical trials, in order to obtain long-term safety, effectiveness, and healthcare utilization information after treatment with Posoleucel or placebo. Recording patient health information over time can help to supplement the original study results and improve the care of patients in the future.

• REC name

  Yorkshire & The Humber - Sheffield Research Ethics Committee

• REC reference

  22/YH/0139

• Date of REC Opinion

  10 Aug 2022

• REC opinion

  Further Information Favourable Opinion